New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
08:03 EDTAMPELuoxis obtains CE Marking for RedoxSYS diagnostic system
Ampio announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained CE Marking in Europe for its RedoxSYS Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body. This regulatory clearance allows Luoxis to engage in market development activities designed to establish the clinical utility of the RedoxSYS System in the critical care setting, and position the company for a successful launch in Europe, which is currently anticipated for 2015.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
07:17 EDTAMPEAmpio's Ampion for osteoarthritis shows positive top-line results
Ampio announced results of the double-blind, multiple injection, vehicle controlled STRUT study at 20 weeks. The forty patient randomized phase of the STRUT study was conducted to assure that multiple injections of Ampion were safe and effective. Each patient received three 4 mL intra-articular injections of Ampion or saline at baseline, 2 weeks and 4 weeks. There were no drug related serious adverse events. The primary endpoint that is required for FDA approval, WOMAC A pain score, improved by 64% from baseline to 20 weeks. Responder rate for Ampion was 79% compared to 47% of saline patients. Data for the larger, multi-site STRIDE study, a similar design to STRUT study, is expected in Q2.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use